As Pfizer's Trumenba rolls out in the U.S., it may get a head start on Novartis' Bexsero, which is still awaiting FDA approval. But the drug giant still doesn't yet have what it needs to build a considerable lead: a recommendation from the CDC's Advisory Committee on Immunization Practices.
When Pfizer and Merck KGaA announced their big immuno-oncology deal Monday, market watchers immediately started extrapolating. The tie-up means Pfizer won't come back for another try at AstraZeneca, some say. But others figure that there's still a solid chance of Pfizer, round two.
Pfizer is determined to be a major player in the fast-emerging field of immuno-oncology, and the pharma giant is paying handsomely to buy its way into an anti-PD-L1 program now underway at Merck KGaA. In a deal announced Monday Pfizer outlined plans to pay a whopping $850 million upfront and up to $2 billion in milestones for the right to co-develop and co-market MSB0010718C and any other IO drugs they put in the pipeline.
With Pfizer's eligibility to bid again for AstraZeneca nearing, the drug giant seems unlikely to make another run at its one-time target, industry-watchers say. But that doesn't mean it isn't prepping a run at someone else.
Pfizer inked a deal with the Bill & Melinda Gates Foundation to roll out a long-acting contraceptive in 69 of the world's poorest countries.
A decade-long class action lawsuit against Pfizer over alleged off-label Neurontin marketing is finally wrapping up, with U.S. District Judge Patti Saris approving a $325 million settlement on Monday.
In an investigative piece published this weekend, the New York Times fingered Pfizer lawyers for wining, dining and otherwise influencing an attorney general to get a favorable lawsuit settlement. Pfizer says the back-and-forth was all aboveboard and part of routine legal negotiations.
The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.
Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think your company is swell. Here's the latest gauge of drugmakers' status in the world of recruiting.
We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.